香港交易及結算所有限公司及香港聯合交易所有限公司對本公告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 鄒 先 生 已 確 認，彼 與 董 事 會 並 無 意 見 分 歧，亦 無 有 關 其 辭 任 的 事 宜 需 提 請 本 公 司 股 東 及 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）垂 注。 董 事 會 進 一 步 宣 佈，在 鄒 先 生 辭 任 聯 席 公 司 秘 書 及 法 律 程 序 文 件 代 理 人 後，陳 靜 雅 女 士（「陳女士」）已 獲 委 任 為 聯 席 公 司 秘 書 及 法 律 程 序 文 件 代 理 人，自2026年3月23日 起 生 效。楊 磊 先 生（「楊先生」）將 繼 續 擔 任 另 一 名 聯 席 公 司 秘 書。 – 1 – 陳 女 士 及 楊 先 生 的 履 歷 詳 情 如 下： QingSong Health Corporation 輕鬆健康集團 （於 開 曼 群 島 註 ...

Financial Performance - Revenue increased by 32.9% from RMB 945.0 million for the year ended December 31, 2024, to RMB 1,255.9 million for the year ended December 31, 2025[4] - Gross profit rose by 20.3% from RMB 361.6 million for the year ended December 31, 2024, to RMB 435.1 million for the year ended December 31, 2025[4] - Adjusted net profit (non-IFRS measure) increased by 9.0% from RMB 84.4 million for the year ended December 31, 2024, to RMB 92.0 million for the year ended December 31, 2025[4] - Loss from continuing operations for the year ended December 31, 2025, was RMB 379.7 million, compared to a profit of RMB 9.0 million for the year ended December 31, 2024, primarily due to changes in the fair value of convertible redeemable preferred shares[4] - Total comprehensive loss for the year ended December 31, 2025, was RMB 379.7 million, compared to a profit of RMB 10.4 million for the year ended December 31, 2024[6] - The company reported a net loss attributable to shareholders of RMB 379,721 thousand for the year ended December 31, 2025, compared to a profit of RMB 10,398 thousand in 2024[7] - Basic loss per share from continuing and discontinued operations was RMB (4.58) for the year ended December 31, 2025, compared to RMB 0.13 in 2024[7] Expenses - Research and development expenses increased from RMB 72.0 million for the year ended December 31, 2024, to RMB 75.6 million for the year ended December 31, 2025[6] - General and administrative expenses slightly increased from RMB 71.6 million for the year ended December 31, 2024, to RMB 72.4 million for the year ended December 31, 2025[6] - Sales and marketing expenses rose from RMB 158.5 million for the year ended December 31, 2024, to RMB 213.4 million for the year ended December 31, 2025[6] - The company incurred a total procurement cost of RMB 756,466,000, which increased from RMB 513,994,000 in the previous year[17] - Total sales and marketing expenses increased by 34.6% from RMB 158.5 million in 2024 to RMB 213.4 million in 2025, driven by higher promotional spending and an increase in sales personnel[73] Assets and Liabilities - Non-current assets totaled RMB 31,362 thousand in 2025, a decrease from RMB 107,505 thousand in 2024[8] - Current assets decreased to RMB 1,160,587 thousand in 2025 from RMB 581,724 thousand in 2024[8] - Current liabilities amounted to RMB 182,502 thousand in 2025, down from RMB 1,898,642 thousand in 2024[9] - The company's net assets were RMB 1,002,222 thousand in 2025, compared to a net liability of RMB (1,218,546) thousand in 2024[9] - As of December 31, 2025, total liabilities amounted to RMB 73,690,000, a significant increase from RMB 34,503,000 in 2024, reflecting a growth of approximately 113%[32] Revenue Breakdown - Revenue from health-related services reached RMB 926,338,000, up 50% from RMB 616,927,000 in the previous year[16] - Insurance technology service revenue was RMB 221,354,000, an increase of 17.6% compared to RMB 188,280,000 in 2024[16] - Health-related services accounted for 73.7% of total revenue in 2025, up from 65.3% in 2024, highlighting its role as a core growth engine[62] Shareholder Information - The company did not declare or recommend any dividends to ordinary shareholders for the years ended December 31, 2025, and 2024[22] - The company has a total of 5,000,000,000 authorized shares, with 800,683,566 shares issued and outstanding as of December 31, 2024, and 206,374,209 shares issued and outstanding as of December 31, 2025[34][35] - The public float of the company is 37.94%, which complies with the minimum requirement of 25% as per the listing rules[122] Corporate Governance - The board expresses gratitude to customers, business partners, employees, and shareholders for their continued support[132] - The company is committed to good corporate governance practices and has adhered to the corporate governance code as outlined in the listing rules[123] - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2025, and recommended approval to the board[125] Future Plans and Projections - The company aims to build a leading integrated health service platform in China, creating a sustainable health service ecosystem for corporate clients and partners[49] - The company plans to launch a clinical decision support AI system by March 2026, enhancing medical decision-making capabilities for physicians[55] - The company plans to utilize the net proceeds from the global offering for operational funding and other general corporate purposes, with a reasonable estimate of usage based on the latest information available[116][114] Digital Marketing and Research - The digital marketing segment achieved a growth rate of 52.1% in 2025 due to the optimization of the health content ecosystem[46] - The company focuses on real-world research project design and in-depth analysis of clinical trial data as part of its digital medical research support services[46] - The company has accumulated over 1.2 million health content creations, with educational content views increasing by 238.1% year-on-year[50] Employee Information - As of December 31, 2025, the company has 213 employees, with employee costs (including director remuneration and share-based payment expenses) amounting to approximately RMB 160.5 million[117] - The company has not encountered any significant labor disputes or difficulties in hiring or retaining employees as of the announcement date[119]

QingSong Health Corporation 輕鬆健康集團 董 事 長、執 行 董 事 兼 首 席 執 行 官 香港交 易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 QingSong Health Corporation 輕鬆健康集團 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2661） 董事會會議日期 輕鬆健康集團（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 2026年3月23日（星 期 一）舉 行，藉 以（其 中 包 括）(i)批准本公司及其附屬公 司截至2025年12月31日 止 年 度 的 全 年 業 績 公 告 及 其 發 佈；及(ii)考慮派付 末 期 股 息（如 有）的 建 議。 承董事會命 楊 胤 香 港，2026年3月10日 截 至 本 公 告 日 期，本 公 司 董 事 會 成 員 包 ...

Group 1 - In 2025, there were 116 new companies listed on A-shares and 119 on Hong Kong stocks, with sectors including AI chips, semiconductor materials, new energy vehicles, chain consumption, and innovative pharmaceuticals [2][3] - The article highlights the increasing presence of female founders and co-founders in these newly listed companies [3] Group 2 - Moore Threads, co-founded by Zhou Yuan, is a notable GPU startup that went public in December 2025 with an initial market value exceeding 300 billion RMB [5][7] - MiniMax, co-founded by Yuan Yeyi, became the fastest AI model company to complete an IPO in January 2026, with a market value of 2230.11 billion RMB [9][10] - Light Health Group, led by Yang Yin, transitioned from a crowdfunding platform to a digital health service provider, achieving a market value of 157.85 billion RMB after its IPO [15][18] - Aixin Yuan Zhi, founded by Qiu Xiaoxin, became the first Chinese edge AI chip company to go public, with a market value of 146.31 billion RMB [20][23] - Baiao Saitou, co-founded by Ni Jian, went public on the STAR Market with a market value of 346.35 billion RMB, focusing on biopharmaceuticals [25][26] - Muxi Co., Ltd., co-founded by Peng Li, is another GPU company that went public in December 2025, with a market value of 2135.41 billion RMB [30][32] - Baoji Pharmaceutical, co-founded by Wang Zheng, achieved a market value of 291.44 billion RMB after its IPO, focusing on gene-engineered drugs [36][38] - Yunji Technology, founded by Zhi Tao, became the first company in the robot service sector to go public, with a market value of 92.79 billion RMB [42][43] - Haibo Shichuang, with Xu Rui as the only female executive, is a leading provider of electrochemical energy storage solutions, listed on the STAR Market [45][46] - Xuan Zhu Biotech, led by Xu Yanjun, focuses on innovative drug development and went public with a market value of 228.60 billion RMB [48][51] Group 3 - The article emphasizes that the presence of women in entrepreneurial and management roles is growing, with many women becoming founders, partners, and core managers in various companies [53] - The narrative celebrates women's contributions to entrepreneurship, suggesting that their impact extends beyond traditional roles [54]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02661 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 206,374,209 0 206,374,209 增加 / 減少 (-) 0 0 本月底結存 206,374,209 0 206,374,209 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | | --- | --- | | 已符合適用的公眾持股量要求（見下方） | ✔ | | 未符合適用的公眾持股量要求（見下方） | | | 根據《主板上市規則》第13.32B條或第19A.28B條 / 《GEM上市規則》第17.37B條或第25.21B條（視情況而定）所載的有關股份類別的最低公眾持股量要求為： | | | 適用的公眾持股量門檻 初始指定門檻 - 上市股份所屬 ...

Group 1 - The Hang Seng Index Company announced the inclusion of Easy Health (02661) in the Hang Seng Composite Index, effective from March 9, 2026, following a quarterly review [1] - Easy Health is likely to be included in the Stock Connect program due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company has successfully transformed from a "crowdfunding platform" to an "AI + health services + insurance protection" ecosystem, significantly increasing the proportion of health service revenue [1] Group 2 - Easy Health has established a unique brand moat in the highly fragmented digital healthcare market by focusing on public health education, differentiating itself from serious medical platforms like Yimaitong [2] - The company has become a starting point in the patient decision-making chain, leveraging its strong brand trust built from its previous crowdfunding platform [2] - The long-term value of the company is expected to further release at current stock price levels, with stock performance primarily dependent on the management's ability to deliver on transformation results [2]

Core Viewpoint - The company has successfully transformed from a "crowdfunding platform" to an "AI + health services + insurance protection" closed-loop ecosystem, significantly increasing the proportion of health service revenue [1] Group 1: Business Transformation - The company has enhanced operational efficiency and scale effects through deep AI integration in content production, precise conversion, and risk control systems, leading to optimized revenue structure and released profitability [1] - The company is expected to have long-term business resilience and anti-cyclical capabilities supported by a multi-payer structure [1] Group 2: Competitive Positioning - In a highly fragmented digital healthcare market, the company has achieved differentiated competition by focusing on public health education, contrasting with serious medical platforms like Yimaitong [1] - The company leverages the strong brand trust accumulated from its previous crowdfunding platform, positioning itself as the starting point in the patient decision-making chain, especially among younger patients who prefer video consultations [1] Group 3: Market Potential - The company's consumer-oriented health content, such as topics on hair loss, sleep, and chronic disease management, has a broader audience and creates a strong psychological positioning at both the scene and patient ends [1] - The company is believed to have further value release potential at the current stock price level, with stock performance primarily dependent on the management's ability to continuously deliver on transformation results [1]

Core Viewpoint - The report from China Merchants Securities indicates that Easy Health (02661) has successfully transformed from a "crowdfunding platform" to a closed-loop ecosystem of "AI + health services + insurance protection," significantly increasing the proportion of health service revenue [1] Group 1: Business Transformation - The company has enhanced its operational efficiency and scale effects through deep AI integration in content production, precise conversion, and risk control systems, leading to optimized revenue structure and released profitability [1] - The firm is rated "Buy" with a target price of HKD 109.4, reflecting confidence in its long-term commercial resilience and counter-cyclical capabilities supported by a multi-payer structure [1] Group 2: Competitive Positioning - In a highly fragmented digital healthcare market, the company has achieved differentiated competition by focusing on public health education, contrasting with serious medical platforms like Yimaitong [1] - Leveraging the strong brand trust built from its origins in crowdfunding, the company has positioned itself as the starting point in the patient decision-making chain, particularly appealing to younger patients who prefer video consultations [1] Group 3: Market Opportunities - The company's consumer-oriented health content, addressing issues like hair loss, sleep, and chronic disease management, has a broader audience and creates a strong psychological presence at both the scene and patient ends [1] - The firm is expected to have further value release potential at current stock price levels, with stock performance primarily dependent on the management's ability to deliver on transformation results [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 輕松健康集團 | | | | | | 呈交日期: | 2026年2月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02661 | 說明 | | | | FF301 第 1 頁 共 10 頁 v 1.2.0 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 500,000,000 USD 0.0001 USD 50,000 增加 / 減少 (-) 0 USD 0 本月底結存 500,000,000 USD 0.0001 USD 50,000 本月底法定/註冊股本總額： USD 50,000 FF301 II. 已發行股份及/或庫存股份變動 ...

QingSong Health Corporation 轻松健康集团 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2661) If you want to receive the Corporate Communications in printed form, please complete and return the reply form on the reverse side of this letter (the "Reply Form") to the Company's Hong Kong share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or send an email t ...